Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

키워드

참고문헌 (10)

1. Younossi ZM, "Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease", J Hepatol, 80, pp.694~701 (2024)
2. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
3. Kim GA, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease : Implication of Janus-faced modernity", Clin Mol Hepatol, 29, pp.831~843 (2023)
4. Tsutsumi T, "MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD : Generalized estimating equation approach", Hepatol Res, 51, pp.1115~1128 (2021)
5. Suzuki H, "Changing from NAFLD to MASLD : Similar prognosis of patients with HCC under atezolizumab", bevacizumab treatment between NAFLD and MASLD, 2024, pp.30, 263~265
6. Suzuki H, "Changing from NAFLD to MASLD : Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD", J Hepatol, 80, pp.e150~e151 (2024)
7. Hagström H, "99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical", J Hepatol, 80, pp.e76~e77 (2024)
8. Nishimura K, "Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score : the suita study", J Atheroscler Thromb, 21, pp.784~798 (2014)
9. D’Agostino RB Sr, "General cardiovascular risk profile for use in primary care : the Framingham Heart Study", Circulation, 117, pp.743~753 (2008)
10. Lee HH, "Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease", Gut, 73, pp.533~540 (2024)

관련 논문AI추천